Thursday, Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day, spotlighting its mRNA-based pipeline and revised financial plans. CEO Stéphane Bancel emphasized the company’s success in respiratory vaccines, stating that Moderna now has five respiratory vaccines with positive Phase 3 results and expects three approvals this year. The company is also focusing on five non-respiratory products, aiming for approvals by 2027. Also Read: Moderna’s Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows. Faced with commercial challenges, Moderna is a…
